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Abstract
The inhibitor kB protein kinase/nuclear factor kB (IKK/NF-kB) signaling pathway is critical for synaptic plasticity. However,
the role of IKK/NF-kB in drug withdrawal-associated conditioned place aversion (CPA) memory is unknown. Here, we
showed that inhibition of IKK/NF-kB by sulphasalazine (SSZ; 10 mM, i.c.v.) selectively blocked the extinction but not
acquisition or expression of morphine-induced CPA in rats. The blockade of CPA extinction induced by SSZ was abolished
by sodium butyrate, an inhibitor of histone deacetylase. Thus, the IKK/NF-kB signaling pathway might play a critical role in
the extinction of morphine-induced CPA in rats and might be a potential pharmacotherapy target for opiate addiction.
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Introduction
Opiate addiction is a chronic relapsing disorder characterized
by compulsive drug seeking and taking motivated by the desire not
only to experience the hedonic effects of the drug but also to avoid
the aversive consequences of drug withdrawal [1,2,3]. Drug
withdrawal-induced aversive memories have been proposed to
play an important role in the compulsivity associated with drug
seeking and taking [4,5,6]. Morphine withdrawal-induced condi-
tioned place aversion (CPA) memory has been widely used in
animals to investigate the negative consequences by drug
withdrawal [7,8]. Behavioral extinction training effectively abol-
ished the expression of morphine-induced CPA [7]. Interestingly,
recent evidence suggested that extinction training as a new
memory did not erase but rather suppressed the conditioned
response [9,10]. The exploration of the underlying mechanism is
important to prevent relapse induced by anhedonia and the
aversive consequences of drug withdrawal.
Previous studies demonstrated the role of the transcription
factor nuclear factor kB (NF-kB) family, which consists of five
members [11,12], in synaptic plasticity and long-term memory
[12,13,14,15,16,17,18]. Specifically, c-Rel, an NF-kB family
transcription factor, is required for hippocampal long-term
synaptic plasticity and contextual fear memory formation [12].
Activation of the transcription factor NF-kB by retrieval is
required for long-term memory reconsolidation [19,20]. NF-kB
signaling played an important role in the extinction of long-term
memory in a context-signal memory model in the crab
Chasmagnathus [21]. Inhibition of NF-kB prior to the extinction
session prevented spontaneous recovery. Our recent study
indicated that NF-kB inhibition impaired the reconsolidation of
morphine-associated reward memory in rats [22]. To produce its
function, NF-kB is translocated into the nucleus and then binds to
the promoter region of target genes [23]. NF-kB was inactivated
when combined with inhibitor kB( I kB) proteins, which could be
phosphorylated by the IkB kinase (IKK) complex [24,25] and then
undergo proteolytic degradation. The IKK complex was recently
shown to regulate chromatin structure. The histone deacetylase
(HDAC) inhibitor sodium butyrate (NaB) blocked the effect of
IKK/NF-kB inhibition on memory reconsolidation [20]. Howev-
er, the role of IKK/NF-kB signaling in the extinction of drug
withdrawal-associated aversive memories is still unknown.
Results
Inhibition of IKK/NF-kB Pathway by SSZ Suppressed the
Extinction of Morphine Withdrawal-associated Aversive
Memory
To investigate the effects of IKK/NF-kB signaling inhibition on
the extinction of morphine-associated aversive memory (Fig. 1A),
four groups of rats (n=8213 per group) which acquired CPA
were infused with sulphasalazine (SSZ; 0, 5, and 10 mM, i.c.v.)
20 min before extinction training [19,21] on day 6 and day 8. The
rats were tested for the expression of CPA (Post-T) 24 h after the
second SSZ infusion. A repeated-measures analysis of variance
(ANOVA) was conducted on CPA scores, with SSZ dose (0, 5, and
10) as the between-subjects factor and test condition (Pre-C, Post-
C, and Post-T) as the within-subjects factor. The results revealed
significant effects of SSZ dose (F2,29=4.090, p,0.05) and test
condition (F2,58=91.97, p,0.001) and a treatment 6 test
condition interaction (F4,58=4.399, p,0.01; Fig. 1B). These
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IKK/NF-kB suppressed the extinction of morphine withdrawal-
associated aversive memory.
Sulfasalazine had no Effect on the Acquisition or
Expression of Morphine Withdrawal-associated Aversive
Memory
As extinction has been suggested to be a new memory, we next
tested whether SSZ affects the acquisition of morphine withdraw-
al-associated CPA. After recovery from surgery, the rats were
randomly divided into two groups (n=9 per group) according to
the Pre-C test. The rats were then trained for morphine-induced
CPA for 4 days, during which SSZ (10 mM, i.c.v.) was infused
20 min before each naloxone injection (Fig. 2A). The expression of
CPA was tested on day 5 (Post-C). A repeated-measures ANOVA
conducted on CPA scores, with SSZ dose (0 and 10 mM) as the
between-subjects factor and test condition (Pre-C and Post-C) as
the within-subjects factor. The results revealed a significant effect
of test condition (F1,16=166.922, p,0.001) but no effect of
treatment (F1,16=0.024, p.0.05) and no treatment 6 test
condition interaction (F1,16=0.039, p.0.05; Fig. 2B), indicating
that IKK/NF-kB activity was not involved in the acquisition of
morphine withdrawal-associated CPA.
The extinction of morphine-induced CPA was blocked by SSZ
infused 20 min before the training session, which might be
attributable to the enhanced expression of CPA but not blockade
of extinction. To exclude this possibility, we tested whether SSZ
affects the expression of CPA. After recovery from surgery, two
groups of rats (n=8 per group) were trained for morphine
withdrawal-associated aversive memory (Fig. 2C). The rats were
tested (Post-T) for the expression of CPA 20 min after SSZ
infusion (0 and 10 mM, i.c.v.). Twenty-four hours later, the rats
were tested again (Re-Test) to exclude the possible delayed effect
of SSZ. A repeated-measures ANOVA was conducted on CPA
scores, with SSZ dose (0 and 10 mM) as the between-subjects
factor and test condition (Pre-C, Post-C, Post-T, and Re-Test) as
the within-subjects factor. The results revealed no significant effect
of treatment (F1,14=0.284, p.0.05) and no treatment 6 test
condition interaction (F3,42=1.148, p.0.05; Fig. 2D), suggesting
that IKK/NF-kB activity was not involved in the expression of
morphine withdrawal-associated aversive memory.
NaB Abolished the Effect of SSZ on Extinction of
Morphine Withdrawal-associated Aversive Memory
Activated IKK/NF-kB signaling affects target gene expression
regulated by HDAC activity. We determined whether NaB, an
HDAC inhibitor, abolishes the effect of SSZ on the extinction of
CPA. After recovery from surgery, the rats were randomly divided
into four groups (n=9210 per group) after the establishment of
CPA (Post-C; Fig. 3A). NaB (0 and 1.2 g/kg, i.p.) [20,22] was
administered 40 min before SSZ infusion (0 and 10 mM, i.c.v.).
Twenty minutes after SSZ infusion, extinction training was
conducted. A repeated-measures ANOVA was conducted on
CPA scores, with SSZ dose (0 and 10 mM) and NaB dose (0 and
1.2 g/kg) as the between-subjects factors and test condition (Pre-C,
Post-C, and Post-T) as the within-subjects factor. The results
revealed significant effects of test condition (F2,72=90.490,
p,0.001) and a NaB dose6SSZ dose6test condition interaction
(F2.72=7.175, p,0.01; Fig. 3B). Conditioned place aversion scores
in the rats that received both SSZ and NaB significantly decreased
24 h after extinction, indicating that NaB abolished the effect of
SSZ on the extinction of CPA.
Sulfasalazine had no Effects on Locomotor Activity or
Reward Per Se
To determine that the effect of SSZ on the extinction of
morphine-induced CPA was not attributable to the possible side
effects of SSZ (e.g., psychoactive actions), we investigated the effect
of SSZ on locomotor activity and place preference in rats. Two
groups of rats (n=728 per group) were tested for changes in
locomotor activity 20 min and 24 h after intracranial administra-
tion of SSZ (Fig. 4A). A repeated-measures ANOVA was used to
analyze locomotor activity, with SSZ dose (0 and 10 mM) as the
between-subjects factor and Test Condition (pretreatment, post-
treatment, and re-test) as the within-subjects factor. The analysis
revealed no significant effects of SSZ (F1,13=0.066, p.0.1) and no
SSZ 6 Test Condition interaction (F2,26=1.383, p.0.1). These
results suggest that the inhibition of IKK/NF-kB activity did not
affect locomotor activity in rats (Fig. 4B).
To exclude the possibility that SSZ inhibited the extinction of
CPA through a possible aversive effect, two groups of rats were
used to determine whether SSZ has any aversive or rewarding
effects per se in a conditioned place preference test (Fig. 4C). In this
experiment, the rats underwent SSZ or vehicle conditioning for
Figure 1. Sulphasalazine (SSZ) suppressed the extinction of
morphine withdrawal-associated aversive memory. (A) Timeline
of experimental procedure. (B) Infusion of the IKK/NF-kB pathway
blocker SSZ (0, 5, and 10 mM) into the cerebral ventricles 20 min before
extinction training suppressed the extinction of morphine withdrawal-
associated aversion memory. The data are expressed as the mean 6
SEM CPA score in seconds (time spent in the drug-paired chamber
minus time spent in the saline-paired chamber) during the CPA tests.
*p,0.01, different from control group (0 mM SSZ treatment group).
Mor, morphine; Nal, naloxone; Sal, saline; Pre-C, pre-conditioning; Post-
C, post-conditioning; Post-T, post-treatment.
doi:10.1371/journal.pone.0039696.g001
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repeated-measures ANOVA was conducted on CPA scores, with
SSZ dose (0 and 10 mM) as the between-subjects factor and Test
Condition (preconditioning and post-conditioning) as the within-
subjects factor. The analysis revealed no significant effect of SSZ
(F1,13=0.001, p.0.5) and no SSZ 6 Test Condition interaction
(F1,13,0.01, p.0.5). These results suggest that the rats showed no
preference for the SSZ-paired chambers in the post-conditioning
test on Day 5, indicating that SSZ administered intracerebroven-
tricularly had no aversive or rewarding effects (Fig. 4D).
Discussion
Collectively, the present study determined the role of the IKK/
NF-kB signaling pathway in morphine withdrawal-associated
CPA. We found that blockade of the IKK/NF-kB signaling
pathway by intracerebroventricular SSZ infusion selectively
suppressed the extinction but not acquisition or expression of
morphine withdrawal-associated CPA, which was blocked by
pretreatment with an HDAC inhibitor, sodium butyrate.
Extinction training has been suggested to form a new memory,
resulting in the loss of the response to cues associated with
emotional stimuli [26]. Extensive research has focused on
discovering the mechanism of extinction, and has provided
evidence of the involvement of the N-methyl-D-aspartate receptor
(NMDAR) [27,28,29]. Activation of NMDARs by glutamate or
acute stress has been shown to activate NF-kB in several brain
structures [30,31,32,33]. The signaling pathway that underlies the
participation of NF-kB in memory formation, including protein
kinase A and its substrate cyclic adenosine monophosphate
response element binding protein, may play a critical role in the
extinction of morphine-induced CPA [34]. Moreover, NF-kB can
affect the growth and morphology of axons and dendrites to affect
the extinction of CPA [35]. Conditioned place aversion is a
hippocampus-dependent memory, and NF-kB may also affect
hippocampal neurogenesis to participate in the morphine-induced
CPA extinction process [36]. A context-signal memory model in
Figure 2. Sulphasalazine (SSZ) had no effect on the acquisition or expression of morphine withdrawal-associated aversive memory.
(A) Timeline of experimental procedure. (B) Infusion of SSZ (0 and 10 mM) into the cerebral ventricles 20 min before CPA training had no effect on the
acquisition of morphine withdrawal-associated aversive memory (p.0.05). (C) Timeline of experiment procedure. (D) Infusion of SSZ (0 and 10 mM)
into the cerebral ventricles 20 min before CPA training had no effects on the expression of morphine withdrawal-associated aversive memory
(p.0.05). The data are expressed as the mean 6 SEM CPA score in seconds (time spent in the drug-paired chamber minus time spent in the saline-
paired chamber) during the CPA tests. Mor, morphine; Nal, naloxone; Sal, saline; Pre-C, pre-conditioning; Post-C, post-conditioning; Post-T, post-
treatment; Re-T, retest.
doi:10.1371/journal.pone.0039696.g002
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extinction. The activation or inhibition of NF-kB was dependent
on the length of exposure to the training context, indicating that
NF-kB was involved in reconsolidation, and NF-kB inhibition was
involved in extinction [21]. de la Fuente et al. found that NF-kB
was required for fear memory reconsolidation, whereas NF-kB
inhibition in the mouse hippocampus enhanced memory extinc-
tion [37]. Interestingly, the results of our experiments showed that
SSZ, an inhibitor of the IKK/NF-kB signaling pathway,
suppressed the extinction of morphine-induced CPA. However,
as the limitation of intracerebroventricular infusion of SSZ used in
the present experiment to inhibit NF-kB, we could not identify the
specific brain subregion where NF-kB played the important role in
the extinction of morphine CPA.
These contradictory results might indicate that the role of NF-
kB in extinction might be memory type-dependent. We propose
the following explanations. First, opioid receptors are involved in
morphine withdrawal-associated aversive memory, so the primar-
ily activated downstream signaling pathways might be different
with the other types of aversive memory models (e.g., fear
memory). Second, evidence has shown that the facilitatory effect of
NF-kB is necessary in memory consolidation and reconsolidation
in crabs and mice [19,20,38,39]. As extinction has been suggested
to be a new type of memory, NF-kB might facilitate the
consolidation of CPA extinction.
Many studies have shown that IKKa could be translocated into
the nucleus to mediate NF-kB-dependent and -independent gene
expression [40,41,42]. SSZ is a well-established antiinflammatory
drug that has been shown to specifically and potently inhibit the
activation of NF-kB [43]. The suppression of NF-kB activity by
SSZ is mediated by direct inhibition of IkB kinases a and b.I t
prevents the phosphorylation and subsequent degradation of the
inhibitory NF-kBI kB b subunit [44], blocks NF-kB translocation
into the nucleus, and suppresses the regulation of chromatin
structure by IKKa [20].
Sodium butyrate is a noncompetitive inhibitor of HDAC
activity [45]. It can halt DNA synthesis, arrest cell proliferation,
alter cell morphology, and regulate gene expression in cultured
cells [46] by increasing histone acetylation [47,48]. It has also
been implicated in depression, anxiety [49], and long-term
memory formation [50] through epigenetic mechanisms. A
recent study reported that intrahippocampal and intra-medial
prefrontal cortex administration of NaB following weak extinc-
tion induced behavioral extinction, indicating that increasing
histone acetylation in the hippocampus-infralimbic network
enhances fear extinction [51]. In the present study, systemic
administration of NaB blocked the SSZ-induced inhibition of
the IKK/NF-kB signaling pathway, which might involve two
possible mechanisms: (i) directly regulating chromatin remodel-
ing by enhancing histone acetylation and (ii) indirectly
regulating gene expression by enhancing NF-kB acetylation
and NF-kB DNA binding activity. Additionally, NaB enhanced
memory retention even after weak training [52]. Interestingly, in
the present study, NaB did not enhance the extinction of
morphine-induced CPA but abolished the SSZ-induced inhibi-
tion of CPA extinction. We suggest that the lack of NaB-
induced enhancement of CPA extinction might be attributable
to a ceiling effect because CPA scores in the control group after
extinction decreased to baseline levels. Moreover, our results
suggest that NF-kB requires the activity of HDAC to exert its
function, specifically to induce the target gene expression
engaged in the extinction of morphine-induced CPA.
The present study has several limitations, the most significant of
which is that we did not present molecular endpoints to
substantiate the theorized molecular mechanisms of the effects
on extinction. Future work that investigates the downstream target
gene expression induced by NF-kB would be helpful to elucidate
the mechanism of extinction of morphine withdrawal-associated
CPA memory.
In summary, the present study demonstrated that the IKK/NF-
kB signaling pathway is involved in the extinction of morphine
withdrawal-associated aversive memory. Inhibition of the IKK/
NF-kB signaling cascade abolished the extinction of morphine
withdrawal-associated CPA, which was reversed by systemic
pretreatment with NaB, an HDAC inhibitor. IKK/NF-kB activity
was shown to be involved in the extinction but not acquisition or
expression of morphine withdrawal-associated CPA, suggesting
that the extinction of morphine withdrawal-associated CPA
depends on IKK/NF-kB activity. However, further studies are
needed to clearly delineate the mechanisms that underlie the role
of the IKK/NF-kB signaling cascade in the extinction of
morphine-associated aversive memory. Nevertheless, these results
suggest that IKK/NF-kB may be a potential target for opioid
relapse prevention.
Figure 3. Sodium butyrate (NaB) abolished the SSZ-induced
inhibition of extinction of morphine withdrawal-associated
aversive memory. (A) Timeline of experiment procedure. (B) Systemic
pretreatment with NaB abolished the SSZ-induced inhibition of
extinction of morphine withdrawal-associated aversive memory. The
data are expressed as the mean 6 SEM CPA score in seconds (time
spent in the drug-paired chamber minus time spent in the saline-paired
chamber) during the CPA tests. *p,0.01, different from control group
(0 mM SSZ treatment group). Sal, saline; SSZ, sulfasalazine; Pre-C, pre-
conditioning; Post-C, post-conditioning; Post-T, post-treatment.
doi:10.1371/journal.pone.0039696.g003
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Animals
Sprague-Dawley male rats, weighing 220–240 g, were obtained
from the Laboratory Animal Center, Peking University Health
Science Center. The rats were housed in groups of five in a
temperature (2362uC) and humidity (5065%) controlled animal
facility with ad libitum access to food and water. The rats were kept
on a reverse 12 hours light/dark cycle. All experimental
procedures were performed in accordance with the National
Institutes of Health Guide for the Care and Use of Laboratory
Animals and were approved by Biomedical Ethics Committee of
Peking University of animal use and protection.
Surgery
During surgery, each rat was implanted with a 23-gauge single
guide cannula (Plastics One, Roanoke, VA, USA) from which the
injector extended 1 mm for placement in the left or right lateral
ventricle after anesthetizing with sodium pentobarbital (50 mg/kg,
i.p.). The stereotaxic coordinates were the following, measured
from the tip of the cannula guide: 1.0 mm from bregma,
61.2 mm lateral from the midline, and 3.5 mm from dura [20].
Animals were habituated to dummy cannula removal and given 7
days of recovery and handling before the start of behavioral
training.
Drugs
Sodium butyrate and SSZ were purchased from Sigma (St.
Louis, MO, USA). Sulfasalazine was freshly dissolved in saline
solution with 10 mM HEPES (pH 7.6) plus 20% dimethyl
sulfoxide (final pH 7.6) [20]. Sodium butyrate was dissolved in
saline solution. For the experiment that investigated the effects of
NaB on CPA memory extinction, the rats were injected with
1.2 g/kg NaB 1 h prior to extinction training [20,22]. Morphine
hydrochloride was obtained from Qinghai Pharmaceuticals
(Qinghai, China). Naloxone hydrochloride was purchased from
Tocris Bioscience (Bristol, UK). All of the drugs were freshly
prepared before the experiments. Naloxone and morphine were
dissolved in saline (Sal, 0.9% NaCl), and both injections were
administered subcutaneously in a 1 ml/kg injection volume that
was selected based on our previous studies [7].
Figure 4. Sulfasalazine had no effect on locomotor activity and no aversive or rewarding effects. (A) Timeline of effects of SSZ on
locomotor activity. Locomotor activity was tested 20 min (Post-T) and 24 h (Re-T) after SSZ administration (10 mM) for 5 min. (B) Sulfasalazine
(10 mM) did not affect locomotor activity 20 min or 24 h after infusion. (C) Timeline of SSZ-induced conditioned place preference/aversive procedure.
A double 2-day-session training procedure was used to test the aversive or rewarding effects of SSZ. (D) Sulfasalazine did not induce any aversion to
or preference for the drug-paired chamber (CPA score), indicating that SSZ had no aversive or rewarding effects. The data are expressed as mean 6
SEM. Pre-T, pre-treatment; Post-T, post-treatment; Re-T, re-test.
doi:10.1371/journal.pone.0039696.g004
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Injections of SSZ (0, 5, and 10 mM) into the lateral ventricle
were performed according to our previous study [22] using
Hamilton syringes connected to 30-gauge injectors (Plastics One).
Sulfasalazine was administered at rate of 1 ml/min for 1 min. After
the injection, the needle was kept in place for another 1 min to
allow for complete diffusion [23].
Naloxone-induced Conditioned Place Aversion
The CPA apparatus used in this study consisted of five identical
three-chamber polyvinylchloride (PVC) boxes [53,54]. Two large
side chambers (27.9 cm length 621.0 cm width 620.9 cm height)
were separated by a smaller chamber (12.1 cm length 621.0 cm
width620.9 cm height with a smooth PVC floor). The two larger
chambers differed in their floor texture (i.e., bar or grid,
respectively) and provided distinct contexts that were paired with
morphine/naloxone or saline injections. Three distinct chambers
were separated by manual guillotine doors that were removed
during the test [55,56].
The CPA training procedure was an unbiased, counterbalanced
protocol that was similar to the one used in previous experiments
[57,58]. The protocol consisted of three phases: preconditioning,
conditioning, and test. In the preconditioning phase (Day 0), the
rats were placed in the middle chamber and allowed to shuttle
between the three chambers in the apparatus for 15 min. The time
spent in each chamber was recorded (Pre-C), and the rats that
showed a strong unconditioned aversion (.180 s) for either
chamber were eliminated from the study [57]. Twenty-four hours
later, a two-session CPA conditioning session was conducted. Each
session included 2 days. On the first day (Day 1 and Day 3), the
rats were injected with morphine (5 mg/kg, s.c.). Four hours later,
they were injected with naloxone (0.3 mg/kg, s.c.) and confined to
the designated chamber (i.e., drug-paired chamber) for 30 min.
On the second day (Day 2 and Day 4), the rats were injected with
saline (1 ml/kg, s.c.). Four hours later, they were given saline
(1 ml/kg, s.c.) and then confined to the chamber (i.e., saline-paired
chamber) opposite to the chamber on the first day for 30 min. On
Day 5, the expression of naloxone-precipitated CPA was tested in
a drug-free state. The testing procedure was the same as the
preconditioning test. The CPA score was defined as the time (in
seconds) spent in the drug-paired chamber minus the time spent in
the saline-paired chamber during the test phase [7,57].
In the experiment that explored the effects of IKK/NF-kB
signaling inhibition on the acquisition of CPA, two groups of rats
(n=9 per group) were administered SSZ (0 or 10 mM in 5 mlo f
vehicle, i.c.v.) 20 min before naloxone injection during every CPA
training session (Fig. 2A). In the experiment that examined the
effects of IKK/NF-kB signaling inhibition on the expression of
CPA, two groups of rats (n =8 per group) that showed morphine
withdrawal-associated aversive memory on Day 5 were adminis-
tered SSZ (0 or 10 mM in 5 ml of vehicle, i.c.v.) 20 min before the
CPA expression test (Post-T) on Day 6 (Fig. 2C). The rats were
tested again on Day 7 (Re-test) to exclude possible delay effects.
Conditioned Place Aversion Extinction Training
The CPA extinction was performed for 4 consecutive days (Day
6–9) under the conditions that was identical to CPA training
(restrictive extinction), with the exception that naloxone and
morphine were replaced by saline. The CPA test (Day 10) was
performed 24 hours after the second extinction training session.
In the experiment that investigated the effects of IKK/NF-kB
signaling inhibition on the extinction of CPA (Fig. 1A), three
groups of rats (n=8213 per group) that had acquired CPA were
given a SSZ microinjection (0, 5, or 10 mM in 5 ml of vehicle,
i.c.v.) 20 min before each extinction training session (Day 6 and
Day 8) [19,21]. Twenty-four hours after extinction training, the
rats were tested for the expression of CPA (Day 10).
In the experiment that determined the possible role of HDAC
activity in the NF-kB-dependent extinction of CPA (Fig. 3A), four
groups of CPA-conditioned rats were administered NaB (0 or
1.2 g/kg, i.p.) and SSZ (0 or 10 mM in 5 ml of vehicle, i.c.v.) 1 h
and 20 min before the naloxone injection during every extinction
training, respectively. The rats were also tested for the expression
of CPA 24 h later on Day 10.
Sulfasalazine-induced Conditioned Place Preference/
Aversion
To exclude the possibility that SSZ has aversive or rewarding
effects per se, two groups of rats were tested for SSZ-induced
conditioned place preference (Fig. 4C). The conditioned place
preference/aversion procedure included preconditioning (Pre-C),
conditioning, and post-conditioning (Post-C) phases. On the first
day (Day 0), the rats were tested for baseline preference/aversion
for 15 min. In the following phase (Day 1–4), the rats received
alternate injections of SSZ (10 mM in 0.5 ml, i.c.v.) and vehicle
(0.5 ml, i.c.v.) 20 min before being confined to the corresponding
chamber for 30 min per day for 4 days. On Day 5, the rats were
tested for SSZ-induced conditioned place preference/aversion
under conditions identical to the Pre-C test.
Effect of SSZ on Locomotor Activity
We used two groups of rats (n=728 per group) to determine
whether SSZ affects locomotor activity in rats (Fig. 4A). The rats
were placed in the testing chamber for 5 min to habituate them to
the procedures used in the test on Day 0. Twenty-four hours later
(Day 1), the rats were tested for 5 min in the testing chamber
20 min (Post-T) after SSZ treatment (0 or 10 mM in 5 mlo f
vehicle, i.c.v.). The rats were tested again on Day 2 to exclude
possible delay effects.
An automated video tracking system (DigBehv-LM4, Shanghai
Jiliang Software Technology Co. Ltd, Shanghai, China), including
eight identical clear Plexiglas chambers (40640665 cm) equipped
with a monochrome video camera on top, was used to measure
locomotor activity. A computer was connected to the chambers to
record the video files. DigBev Analysis Software was used to
analyze the video files. Locomotor activity is expressed as the total
distance traveled during the 5 min test.
Statistical Analysis
All of the data are expressed as mean 6 SEM. The statistical
analysis was performed using ANOVA with appropriate between-
and within-subjects factors for the different experiments (see
Results). Post hoc analyses of significant effects in the ANOVA were
performed using the Tukey test. Values of p,0.05 were considered
statistically significant.
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